Innovations and development of Covid-19 vaccines: A patent review

doi:10.1016/j.jiph.2021.10.021

Review

. 2022 Jan;15(1):123-131.

doi: 10.1016/j.jiph.2021.10.021. Epub 2021 Oct 23.

Innovations and development of Covid-19 vaccines: A patent review

Ahmed S Alshrari¹, Shuaibu A Hudu², Mohd Imran³, Syed Mohammed Basheeruddin Asdaq⁴, Alreshidi M Ali⁵, Syed Imam Rabbani⁶

Affiliations

¹ Medical Laboratory Technology Department, Faculty of Applied Medical Science, Northern Border University, Arar, Saudi Arabia. Electronic address: ahmed.alsharari@nbu.edu.sa.
² Department of Medical Microbiology and Parasitology, Faculty of Basic Clinical Sciences, College of Health Sciences, Usmanu Danfodiyo University, Sokoto 840232, Sokoto State, Nigeria. Electronic address: drhudu@yahoo.com.
³ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha, Saudi Arabia. Electronic address: imran.pchem@gmail.com.
⁴ Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, 13713 Riyadh, Saudi Arabia. Electronic address: sasdaq@gmail.com.
⁵ Department of Medical Laboratory Sciences, Sulaiman ALrajhi University, Albukairah, Saudi Arabia. Electronic address: ma.alreshidi@sr.edu.sa.
⁶ Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia. Electronic address: syedrabbani09@yahoo.com.

PMID: 34742639
PMCID: PMC8539827
DOI: 10.1016/j.jiph.2021.10.021

Review

Innovations and development of Covid-19 vaccines: A patent review

Ahmed S Alshrari et al. J Infect Public Health. 2022 Jan.

. 2022 Jan;15(1):123-131.

doi: 10.1016/j.jiph.2021.10.021. Epub 2021 Oct 23.

Authors

Ahmed S Alshrari¹, Shuaibu A Hudu², Mohd Imran³, Syed Mohammed Basheeruddin Asdaq⁴, Alreshidi M Ali⁵, Syed Imam Rabbani⁶

Affiliations

¹ Medical Laboratory Technology Department, Faculty of Applied Medical Science, Northern Border University, Arar, Saudi Arabia. Electronic address: ahmed.alsharari@nbu.edu.sa.
² Department of Medical Microbiology and Parasitology, Faculty of Basic Clinical Sciences, College of Health Sciences, Usmanu Danfodiyo University, Sokoto 840232, Sokoto State, Nigeria. Electronic address: drhudu@yahoo.com.
³ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha, Saudi Arabia. Electronic address: imran.pchem@gmail.com.
⁴ Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, 13713 Riyadh, Saudi Arabia. Electronic address: sasdaq@gmail.com.
⁵ Department of Medical Laboratory Sciences, Sulaiman ALrajhi University, Albukairah, Saudi Arabia. Electronic address: ma.alreshidi@sr.edu.sa.
⁶ Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia. Electronic address: syedrabbani09@yahoo.com.

PMID: 34742639
PMCID: PMC8539827
DOI: 10.1016/j.jiph.2021.10.021

Abstract

More than 125 million confirmed cases of COVID-19 have been reported globally with rising cases in all countries since the first case was reported. A vaccine is the best measure for the effective prevention and control of COVID-19. There are more than 292 COVID-19 candidates' vaccines being developed as of July 2021 of which 184 are in human preclinical trials. A patent provides protection and a marketing monopoly to the inventor of an invention for a specified period. Therefore, vaccine developers, including Moderna, BioNTech, Janssen, Inovio, and Gamaleya also filed patent applications for the protection of their vaccines. This review aims to provide an insight into the patent literature of COVID-19 vaccines. The patent search was done using Patentscope and Espacenet databases. The results have revealed that most of the key players have patented their inventive COVID-19 vaccine. Many patent applications related to COVID-19 vaccines developed via different technologies (DNA, RNA, virus, bacteria, and protein subunit) have also been filed. The publication of a normal patent application takes place after 18 months of its filing. Therefore, many patents/patent applications related to the COVID-19 vaccine developed through different technology may come into the public domain in the coming days.

Keywords: COVID-19; Development; Innovation; Patent; SARS-CoV-2 viral spike (S) protein; Vaccine; Viral receptor-binding domain.

PubMed Disclaimer

Cited by

Molecular docking analysis of quercetin with known CoVid-19 targets.
Chandran SCS, Christopher I, Sounderraajan A, Murugesan V, Sabapathy I, Periyasamy V, Manikkam R. Chandran SCS, et al. Bioinformation. 2023 Nov 30;19(11):1081-1085. doi: 10.6026/973206300191081. eCollection 2023. Bioinformation. 2023. PMID: 38046509 Free PMC article.
Parental COVID-19 Vaccine Hesitancy for Children and Its Influencing Factors: A Riyadh-Based Cross-Sectional Study.
Almuqbil M, Al-Asmi R, AlRamly S, Hijazi N, Alotaibi H, AlMubarak A, AlAnezi K, Al-Rowaili M, Al-Yamani M, Duwaidi BS, Alshammari DR, Alabdulsalam AM, Almutairi JA, Alasmari FM, Asdaq SMB. Almuqbil M, et al. Vaccines (Basel). 2023 Feb 23;11(3):518. doi: 10.3390/vaccines11030518. Vaccines (Basel). 2023. PMID: 36992102 Free PMC article.
The evolution of the global COVID-19 epidemic in Morocco and understanding the different therapeutic approaches of chitosan in the control of the pandemic.
Ait Hamdan Y, El Amerany F, Desbrières J, Aghrinane A, Oudadesse H, Rhazi M. Ait Hamdan Y, et al. Polym Bull (Berl). 2022 Nov 21:1-27. doi: 10.1007/s00289-022-04579-3. Online ahead of print. Polym Bull (Berl). 2022. PMID: 36466080 Free PMC article. Review.
The impact of the COVID-19 pandemic on parents' perceptions and acceptance of routine childhood vaccination in Canada: A national longitudinal study.
Humble RM, Scott SD, Dubé E, Olson J, MacDonald SE. Humble RM, et al. Vaccine. 2023 Jan 9;41(2):407-415. doi: 10.1016/j.vaccine.2022.11.052. Epub 2022 Nov 24. Vaccine. 2023. PMID: 36462954 Free PMC article.
The effect of Ni gella sativa and vitamin D3 supplementation on the clinical outcome in COVID-19 patients: A randomized controlled clinical trial.
Said SA, Abdulbaset A, El-Kholy AA, Besckales O, Sabri NA. Said SA, et al. Front Pharmacol. 2022 Nov 8;13:1011522. doi: 10.3389/fphar.2022.1011522. eCollection 2022. Front Pharmacol. 2022. PMID: 36425571 Free PMC article.

See all "Cited by" articles

References

1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 - PMC - PubMed
1. WHO . 2020. Novel coronavirus (2019-nCoV). Situation report–22. Data as reported by 11 February 2020.
1. Fagherazzi G., Goetzinger C., Rashid M.A., Aguayo G.A., Huiart L. Digital health strategies to fight COVID-19 worldwide: challenges, recommendations, and a call for papers. J Med Internet Res. 2020;22(6):e19284. - PMC - PubMed
1. Miller I.F., Becker A.D., Grenfell B.T., Metcalf C.J.E. Disease and healthcare burden of COVID-19 in the United States. Nat Med. 2020;26(8):1212–1217. - PubMed
1. Yang J., Chen X., Deng X., Chen Z., Gong H., Yan H., et al. Disease burden and clinical severity of the first pandemic wave of COVID-19 in Wuhan, China. Nat Commun. 2020;11(1):1–10. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 - PMC - PubMed

[2] Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 - PMC - PubMed

[3] WHO . 2020. Novel coronavirus (2019-nCoV). Situation report–22. Data as reported by 11 February 2020.

[4] WHO . 2020. Novel coronavirus (2019-nCoV). Situation report–22. Data as reported by 11 February 2020.

[5] Fagherazzi G., Goetzinger C., Rashid M.A., Aguayo G.A., Huiart L. Digital health strategies to fight COVID-19 worldwide: challenges, recommendations, and a call for papers. J Med Internet Res. 2020;22(6):e19284. - PMC - PubMed

[6] Fagherazzi G., Goetzinger C., Rashid M.A., Aguayo G.A., Huiart L. Digital health strategies to fight COVID-19 worldwide: challenges, recommendations, and a call for papers. J Med Internet Res. 2020;22(6):e19284. - PMC - PubMed

[7] Miller I.F., Becker A.D., Grenfell B.T., Metcalf C.J.E. Disease and healthcare burden of COVID-19 in the United States. Nat Med. 2020;26(8):1212–1217. - PubMed

[8] Miller I.F., Becker A.D., Grenfell B.T., Metcalf C.J.E. Disease and healthcare burden of COVID-19 in the United States. Nat Med. 2020;26(8):1212–1217. - PubMed

[9] Yang J., Chen X., Deng X., Chen Z., Gong H., Yan H., et al. Disease burden and clinical severity of the first pandemic wave of COVID-19 in Wuhan, China. Nat Commun. 2020;11(1):1–10. - PMC - PubMed

[10] Yang J., Chen X., Deng X., Chen Z., Gong H., Yan H., et al. Disease burden and clinical severity of the first pandemic wave of COVID-19 in Wuhan, China. Nat Commun. 2020;11(1):1–10. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Innovations and development of Covid-19 vaccines: A patent review

Affiliations

Innovations and development of Covid-19 vaccines: A patent review

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous